Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
The Lithuanian Ministry of Health and EFPIA, the European Federation of Pharmaceutical Industries and Associations (their member in Lithuania - the Association of Innovative Pharmaceutical Industry (IFPA), have today announced a significant new Joint Working Agreement that paves the way for protecting future health and growth in Lithuanian.
The agreement is a concrete step towards delivering the vision of health and sustainable growth set out in the Vilnius Declaration, which was signed during Lithuania's Presidency of the EU last year. It sets out a series of measure to safeguard future innovation and healthcare, including establishing a specific ‘Reimbursement Budget’ that will reflect and be proportionate to both GDP growth and increase in overall public health care spending.
Lithuanian Minister of Health Vytenis Povilas Andriukaitis stated: “We are creating a sustainable health care system that is prone to demographic and economic challenges, that promptly responds to current health threats, that incorporates newest technologies and best medical practices. The Ministry of Health and EFPIA working together means new treatment options for the patients, greater transparency for the healthcare industry and meaningful cooperation with innovative businesses.”
Through partnering on a holistic life sciences strategy, EFPIA and the Lithuanian Ministry of Health intend to make Lithuania a more attractive location for life sciences investment, and to support a healthy population through the creation of more effective, efficient and sustainable health systems.
EFPIA Director General Richard Bergström stated: “Our industry has entered into a number of agreements with European governments, but the Lithuanian agreement has achieved a new progressive, gold standard in collaboration for better health outcomes. It signifies a new dawn in our industry’s partnerships, as it delivers a much more comprehensive solution to meeting the health and economic needs of citizens. I urge other nations to learn from the Lithuanian approach.”
The agreement was born from a recognised need to protect patients, public health and medical progress in Lithuania.
The Joint Working Agreement, available in full via the link provided here, sets out points of action designed to: